Mulholland Michael D. 4/A

Accession 0001807094-20-000030

CIK 0001175680other

View on SEC.gov Company Profile

Filed

Dec 20, 7:00 PM ET

Accepted

Dec 21, 9:55 PM ET

Size

35.4 KB

Accession

0001807094-20-000030

Insider Transaction Report

Form 4/AAmended

Period: 2020-12-17

CytoDyn Inc.CYDY

MULHOLLAND MICHAEL D

CFO, Treasurer and Secretary

Transactions

Exercise/Conversion
Common Stock
2020-12-21$0.87/sh+88,199$76,733→ 873,878 total
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-21+88,199→ 161,801 total
Exercise: $0.87From: 2020-12-21Exp: 2025-11-23→ Common Stock (88,199 underlying)
Exercise/Conversion
Common Stock
2020-12-21$0.80/sh+300,000$240,000→ 785,679 total
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-17+32,000→ 155,500 total
Exercise: $0.39From: 2020-12-17Exp: 2029-10-07→ Common Stock (32,000 underlying)
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-18+233,100→ 116,900 total
Exercise: $0.49From: 2020-12-18Exp: 2028-06-08→ Common Stock (233,100 underlying)
Exercise/Conversion
Common Stock
2020-12-17$0.39/sh+32,000$12,480→ 316,081 total
Exercise/Conversion
Common Stock
2020-12-18$0.39/sh+155,500$60,645→ 439,581 total
Exercise/Conversion
Common Stock
2020-12-18$0.49/sh+233,100$114,219→ 672,681 total
Exercise/Conversion
Common Stock
2020-12-18$0.57/sh+98,402$56,089→ 771,083 total
Sale
Common Stock
2020-12-18$4.95/sh−487,002$2,411,439→ 284,081 total
Sale
Common Stock
2020-12-21$5.58/sh−585,797$3,269,919→ 284,081 total
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-18+155,500→ 0 total
Exercise: $0.39From: 2020-12-18Exp: 2029-10-07→ Common Stock (155,500 underlying)
Sale
Common Stock
2020-12-17$4.55/sh−32,000$145,674→ 284,081 total
Exercise/Conversion
Common Stock
2020-12-21$0.57/sh+201,598$114,911→ 485,679 total
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-18+98,402→ 201,598 total
Exercise: $0.57From: 2020-12-18Exp: 2027-06-01→ Common Stock (98,402 underlying)
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-21+201,598→ 0 total
Exercise: $0.57From: 2020-12-21Exp: 2027-06-01→ Common Stock (201,598 underlying)
Exercise/Conversion
Non-qualified Stock Option (right to buy)
2020-12-21+300,000→ 0 total
Exercise: $0.80From: 2020-12-21Exp: 2023-02-15→ Common Stock (300,000 underlying)

Footnotes (9)

[F1]All shares sold and reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan the reporting person entered into on November 12, 2020. The plan provides for periodic sales by the reporting person's broker without further action by the reporting person.
[F2]This transaction was executed in multiple trades at prices ranging from $4.50 to $4.68. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $4.80 to $5.08. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $5.03 to $6.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]The reported option became fully vested on October 7, 2020.
[F6]Sixty-seven percent (67%) of the reported option became fully vested on June 8, 2020; the shares remaining subject to this option vest on June 8, 2021.
[F7]The reported option became fully vested on June 1, 2020.
[F8]The reported option became fully vested on grant date.
[F9]Fifty percent (50%) of the reported option became fully vested in 2016 and 50% was forfeited.

Documents

1 file

4
primary_doc.xml
PRIMARY DOCUMENT

Issuer

CytoDyn Inc.

CIK 0001175680

→

Entity typeother

Related Parties

filerCIK 0001257911

Filing Metadata

Form type: 4/A
Filed: Dec 20, 7:00 PM ET
Accepted: Dec 21, 9:55 PM ET
Size: 35.4 KB

View on SEC.gov